| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Departments of Medicine, 2Physiology and Biophysics, 3Physiological Optics, 4Neurobiology, and 5Ophthalmology, University of Alabama, Birmingham, Alabama.
PURPOSE. To identify and characterize the early alterations of the ERG oscillatory potentials (OPs) under conditions of poor glycemic control associated with diabetes in an animal model. To characterize and correlate the a- and b-wave properties of the ERGs of diabetic animals in parallel with the changes in oscillatory potentials.
METHODS. Blood sugars, weights, and ERGs were measured for a group of rats each week for 3 weeks to obtain baseline information. A single injection of streptozotocin was given to the experimental animals. Weights, blood sugar, glycosylated hemoglobin, and detailed ERGs were recorded weekly for up to 12 weeks in control and experimental animals.
RESULTS. OP kinetics were found to be inherently related to amplitude. Amplitude-matched OPs were delayed in diabetic animals when compared with baseline data from the same animal. The kinetics of OPs in control animals stayed the same or were slightly accelerated relative to their baseline values. For a given recording condition, OP kinetics were very stable over time and this stability was not disturbed in diabetic animals. Diabetic animals showed a small but significant delay in the a-wave, but no change in b-wave timing. The sensitivity of the b-wave was reduced twofold, but that of the a-wave was not changed.
CONCLUSIONS. OPs have been used to evaluate retinal function in both diabetic models and patients. The comparison of amplitude-matched OPs is a robust determinant of changes in kinetics. Researchers and clinicians who use OPs may wish to consider the relationship between OP amplitude and kinetics to avoid confounding assessments of abnormalities. The amplitude versus kinetics relationship does not change form in diabetic animals; it is merely shifted (delayed) on the time axis.
This article has been cited by other articles:
|
|
 |
|
  M Parravano, F Oddone, D Mineo, M Centofanti, P Borboni, R Lauro, L Tanga, and G Manni The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes Br. J. Ophthalmol., December 1, 2008; 92(12): 1656 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Kern and A. J. Barber Retinal ganglion cells in diabetes J. Physiol., September 15, 2008; 586(18): 4401 - 4408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kohzaki, A. J. Vingrys, and B. V. Bui Early Inner Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3595 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurihara, Y. Ozawa, N. Nagai, K. Shinoda, K. Noda, Y. Imamura, K. Tsubota, H. Okano, Y. Oike, and S. Ishida Angiotensin II Type 1 Receptor Signaling Contributes to Synaptophysin Degradation and Neuronal Dysfunction in the Diabetic Retina Diabetes, August 1, 2008; 57(8): 2191 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Akula, J. A. Mocko, A. Moskowitz, R. M. Hansen, and A. B. Fulton The Oscillatory Potentials of the Dark-Adapted Electroretinogram in Retinopathy of Prematurity Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5788 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Kern, C. M. Miller, Y. Du, L. Zheng, S. Mohr, S. L. Ball, M. Kim, J. A. Jamison, and D. P. Bingaman Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology Diabetes, February 1, 2007; 56(2): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liu, J. D. Akula, R. M. Hansen, A. Moskowitz, M. S. Kleinman, and A. B. Fulton Development of the Electroretinographic Oscillatory Potentials in Normal and ROP Rats Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5447 - 5452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. de Gooyer, K. A. Stevenson, P. Humphries, D. A. C. Simpson, T. A. Gardiner, and A. W. Stitt Retinopathy Is Reduced during Experimental Diabetes in a Mouse Model of Outer Retinal Degeneration Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5561 - 5568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Ramsey, H. Ripps, and H. Qian An Electrophysiological Study of Retinal Function in the Diabetic Female Rat Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 5116 - 5124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. van Eeden, L. B. G. Tee, S. Lukehurst, C.-M. Lai, E. P. Rakoczy, L. D. Beazley, and S. A. Dunlop Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4638 - 4645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gastinger, R. S. J. Singh, and A. J. Barber Loss of Cholinergic and Dopaminergic Amacrine Cells in Streptozotocin-Diabetic Rat and Ins2Akita-Diabetic Mouse Retinas. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3143 - 3150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lei, G. Yao, K. Zhang, K. J. Hofeldt, and B. Chang Study of rod- and cone-driven oscillatory potentials in mice. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2732 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Da and A. S. Verkman Aquaporin-4 Gene Disruption in Mice Protects against Impaired Retinal Function and Cell Death after Ischemia Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4477 - 4483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Phipps, E. L. Fletcher, and A. J. Vingrys Paired-Flash Identification of Rod and Cone Dysfunction in the Diabetic Rat Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4592 - 4600. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
